Brief: Omeros Corporation To Terminate Yartemlea Compassionate-Use Program In Europe Due To US Demand
16/10/2026 11:34
BRIEF-Omeros Corporation To Terminate Yartemlea Compassionate-Use Program In Europe Due To US Demand Oct 16 (Reuters) - Omeros Corporation OMER.O:
OMEROS CORPORATION RECEIVES CHMP NEGATIVE OPINION FOLLOWING RE-EXAMINATION OF EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR NARSOPLIMAB IN TA-TMA
OMEROS CORPORATION - TO TERMINATE YARTEMLEA COMPASSIONATE-USE PROGRAM IN EUROPE DUE TO U.S. DEMAND
OMEROS CORPORATION - PLANS CLINICAL STUDIES IN ARDS AND HIGH-RISK TA-TMA IN PEDIATRIC PATIENTS LATER THIS YEAR
Source text: ID:nBw6dP86Ra
Further company coverage: OMER.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Omeros
See all newsBrief: Omeros Corporation To Terminate Yartemlea Compassionate-Use Program In Europe Due To US Demand
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports
U.S. STOCKS ON THE MOVE-Five Below, Salesforce, IBM, Akamai Technologies